IN2014DN10449A - - Google Patents
Info
- Publication number
- IN2014DN10449A IN2014DN10449A IN10449DEN2014A IN2014DN10449A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A IN 10449DEN2014 A IN10449DEN2014 A IN 10449DEN2014A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A
- Authority
- IN
- India
- Prior art keywords
- medicaments
- medicament
- substituents
- salt
- compound
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012078933 | 2012-07-20 | ||
| CN2013078309 | 2013-06-28 | ||
| PCT/IB2013/055916 WO2014013469A1 (fr) | 2012-07-20 | 2013-07-18 | Dérivés de carbamate/urée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10449A true IN2014DN10449A (fr) | 2015-08-21 |
Family
ID=49263333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10449DEN2014 IN2014DN10449A (fr) | 2012-07-20 | 2013-07-18 |
Country Status (42)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR088256A1 (es) | 2011-10-08 | 2014-05-21 | Novartis Ag | Derivados de carbamato / urea como antagonistas del receptor h3 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| EP3391886A1 (fr) * | 2017-04-19 | 2018-10-24 | Novartis AG | Utilisation d'un agoniste inverse h3r pour le traitement de trouble du travail par équipes |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| EP3863619A1 (fr) | 2018-10-11 | 2021-08-18 | Novartis AG | Utilisation d'un agoniste inverse de h3r pour le traitement d'une somnolence diurne excessive associée à la maladie de parkinson (mp) |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| WO2022113008A1 (fr) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Antagonistes/agonistes inverses du récepteur h3 de l'histamine pour le traitement d'un trouble du spectre autistique |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567518B1 (fr) | 1984-07-11 | 1987-11-13 | Sanofi Sa | Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent |
| TW301607B (fr) | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| MXPA02007036A (es) * | 2000-01-20 | 2002-12-13 | Eisai Co Ltd | Compuesto de piperidina novedoso y composicion farmaceutica del mismo. |
| CN1298715C (zh) | 2001-03-13 | 2007-02-07 | 先灵公司 | 作为组胺h3拮抗剂的非咪唑化合物 |
| CA2514733A1 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
| KR20050121268A (ko) | 2003-04-23 | 2005-12-26 | 글락소 그룹 리미티드 | 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도 |
| UA83416C2 (en) | 2004-02-13 | 2008-07-10 | Баниу Фармасьютикал Ко., Лтд. | Fused ring 4-oxopyrimidine derivative |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| US7528258B2 (en) | 2004-09-02 | 2009-05-05 | Teva Pharmaceutical Industries Ltd | Preparation of olmesartan medoxomil |
| CA2575177A1 (fr) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Epuration d'olmesartan medoxomil |
| EP1909797A4 (fr) | 2005-08-02 | 2013-02-27 | Neurogen Corp | Dipipérazinyl cétones et analogues apparentés |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063934A1 (fr) | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | Compose heterocyclique alicyclique |
| CN102015668A (zh) * | 2007-12-05 | 2011-04-13 | 阿斯利康(瑞典)有限公司 | 用作瘦蛋白受体调节剂的哌嗪衍生物及其用途 |
| TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| WO2009142732A2 (fr) | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h<sb>3</sb>) |
| JP5677325B2 (ja) | 2010-01-22 | 2015-02-25 | 大鵬薬品工業株式会社 | Ｐｇｄｓ阻害作用を有するピペラジン化合物 |
| TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| AR088256A1 (es) * | 2011-10-08 | 2014-05-21 | Novartis Ag | Derivados de carbamato / urea como antagonistas del receptor h3 |
| US9034874B2 (en) * | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
-
2013
- 2013-07-17 US US13/944,354 patent/US9034874B2/en active Active
- 2013-07-18 MX MX2015000903A patent/MX362059B/es active IP Right Grant
- 2013-07-18 KR KR1020157001045A patent/KR102150739B1/ko active IP Right Grant
- 2013-07-18 EA EA201590250A patent/EA026091B1/ru not_active IP Right Cessation
- 2013-07-18 MY MYPI2014003308A patent/MY168752A/en unknown
- 2013-07-18 PE PE2015000045A patent/PE20151155A1/es active IP Right Grant
- 2013-07-18 NO NO13770709A patent/NO2875016T3/no unknown
- 2013-07-18 DK DK13770709.7T patent/DK2875016T3/da active
- 2013-07-18 CU CUP2015000006A patent/CU24248B1/es unknown
- 2013-07-18 SI SI201330787T patent/SI2875016T1/sl unknown
- 2013-07-18 NZ NZ702346A patent/NZ702346A/en not_active IP Right Cessation
- 2013-07-18 SG SG10201700188PA patent/SG10201700188PA/en unknown
- 2013-07-18 CN CN201380038422.1A patent/CN104470911B/zh active Active
- 2013-07-18 HU HUE13770709A patent/HUE035592T2/en unknown
- 2013-07-18 ES ES13770709.7T patent/ES2648512T3/es active Active
- 2013-07-18 BR BR112015001207-8A patent/BR112015001207B1/pt not_active IP Right Cessation
- 2013-07-18 PL PL13770709T patent/PL2875016T3/pl unknown
- 2013-07-18 WO PCT/IB2013/055916 patent/WO2014013469A1/fr active Application Filing
- 2013-07-18 SG SG11201408020RA patent/SG11201408020RA/en unknown
- 2013-07-18 CA CA2878006A patent/CA2878006C/fr active Active
- 2013-07-18 EP EP13770709.7A patent/EP2875016B1/fr active Active
- 2013-07-18 JP JP2015522234A patent/JP6203841B2/ja active Active
- 2013-07-18 IN IN10449DEN2014 patent/IN2014DN10449A/en unknown
- 2013-07-18 AU AU2013291617A patent/AU2013291617B2/en not_active Ceased
- 2013-07-18 LT LTEP13770709.7T patent/LT2875016T/lt unknown
- 2013-07-18 AP AP2014008109A patent/AP3710A/en active
- 2013-07-18 PT PT137707097T patent/PT2875016T/pt unknown
- 2013-07-18 RS RS20171048A patent/RS56479B1/sr unknown
- 2013-07-19 UY UY0001034921A patent/UY34921A/es unknown
- 2013-07-19 TW TW102125975A patent/TWI597276B/zh active
- 2013-07-21 JO JOP/2013/0218A patent/JO3439B1/ar active
- 2013-07-22 AR ARP130102583A patent/AR092354A1/es active IP Right Grant
-
2014
- 2014-11-27 ZA ZA2014/08805A patent/ZA201408805B/en unknown
- 2014-11-28 TN TN2014000497A patent/TN2014000497A1/fr unknown
- 2014-12-05 PH PH12014502743A patent/PH12014502743B1/en unknown
-
2015
- 2015-01-09 CL CL2015000056A patent/CL2015000056A1/es unknown
- 2015-01-11 IL IL236656A patent/IL236656A/en active IP Right Grant
- 2015-01-20 CR CR20150019A patent/CR20150019A/es unknown
- 2015-01-20 CO CO15009915A patent/CO7170173A2/es unknown
- 2015-01-20 GT GT201500012A patent/GT201500012A/es unknown
- 2015-04-14 US US14/685,926 patent/US9273026B2/en active Active
- 2015-05-28 HK HK15105099.2A patent/HK1204609A1/xx not_active IP Right Cessation
-
2016
- 2016-02-22 US US15/049,739 patent/US9624192B2/en active Active
-
2017
- 2017-03-07 US US15/452,430 patent/US20170275264A1/en not_active Abandoned
- 2017-10-25 CY CY20171101112T patent/CY1119492T1/el unknown
- 2017-11-06 HR HRP20171692TT patent/HRP20171692T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03998A (fr) | ||
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| IN2014DN10449A (fr) | ||
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| PH12015501083B1 (en) | Novel pyridine derivatives | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| MX343706B (es) | Derivados heterocíclicos novedosos. | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12015501843A1 (en) | Novel pyrazol derivatives | |
| IN2015DN01119A (fr) | ||
| IN2014DN01629A (fr) | ||
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| MY174000A (en) | Novel pyridine derivatives | |
| MX362879B (es) | Usos novedosos. | |
| MX2016004934A (es) | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| PH12015500585A1 (en) | Modified hyaluronic acid derivatives and use thereof | |
| IN2014DN10669A (fr) | ||
| MX363458B (es) | Nuevos derivados de tetrazolona. | |
| MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
| PH12015500373B1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
| MX348841B (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| TN2013000089A1 (en) | Triazine-oxadiazoles | |
| MA37778A1 (fr) | Dérivés de carbamate/urée |